HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 09, September 2017 – Infectious Diseases       » Breakthrough in pig-to-human organ transplant       » Silk-based wearable body sensors developed by Tsinghua researchers       » First AI-assisted treatment center in Hefei city       » Breakthrough immunotherapy for Chronic Hepatitis B virus infection       » First in Asia - Launch of multi-centre lung cancer research platform       » NUS establishes additive manufacturing facilities for biomedical applications      
EYE on CHINA
Ascletis gains China market rights from Janssen to a clinical stage HIV protease inhibitor
A scletis announced that the company has licensed develop- ment, manufacturing and commercialization rights from Assent R&D Ireland to TMC310911, a next-generation HIV protease inhibitor (PI). The agreement provides Ascletis with exclusive rights to develop and commercialize TMC310911 in Greater China, including mainland China and Macau. Janssen will retain all rights in the rest of the world and is eligible to receive royalties based on product sales in Greater China.

“This licensing agreement for TMC310911 adds a third drug candidate in late-stage development to the Ascletis pipeline, which aims to provide innovative therapeutics for important medical needs in China,” said Jinzi J. Wu, Ph.D., Ascletis President and Chief Executive Officer. “Based on research to date, we believe that TMC310911 has the potential to offer a new standard-of-care, especially for HIV-infected patients exhibiting multi-drug resistance to current PIs.”

Published research has shown that TMC310911 offers a higher genetic barrier to the development of resistance than any existing HIV PIs. TMC310911 also exhibits broader activity against multi-PI resistant recombinant clinical isolates of HIV than any currently approved PI, including darunavir, the current standard of care. Moreover, three clinical studies completed by Janssen, including a Phase IIa study, showed TMC310911 to have a favorable safety and tolerability profile and demonstrated clinical proof-of-concept in treatment naïve, HIV positive patients.

Click here for the complete issue.

NEWS CRUNCH  
news Johnson & Johnson Innovation announces winners of the Singapore QuickFire Challenge in collaboration with ETPL and SMART
news Singapore leads the world in progress toward the health Sustainable Development Goals (SDGs)
news HIMSS AsiaPac17 conference and exhibition returns to address Asia's health IT challenges
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy